Real-world evidence of measurable residual disease assessment in multiple myeloma.
Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Pérez-Montaña A, Casanova M, Breña Atienza J, Garcia A, de Arriba F, Martínez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernández R, Alvarez Rivas MA, Capote FJ, García-Sánchez R, Pérez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martínez-López J, Mateos MV, San-Miguel JF.
Cedena MT, et al. Among authors: garcia a.
Blood Adv. 2025 Dec 11:bloodadvances.2025018454. doi: 10.1182/bloodadvances.2025018454. Online ahead of print.
Blood Adv. 2025.
PMID: 41380099
No abstract available.